ID

16663

Description

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00292253

Lien

https://clinicaltrials.gov/show/NCT00292253

Mots-clés

  1. 30/07/2016 30/07/2016 -
Téléchargé le

30 juillet 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Multiple Sclerosis, Relapsing-remitting NCT00292253

Eligibility Multiple Sclerosis, Relapsing-remitting NCT00292253

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
greater than or equal to 18 years of age
Description

age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
has relapsing-remitting ms
Description

relapsing-remitting ms

Type de données

boolean

Alias
UMLS CUI [1]
C0751967
are willing and able to comply with the protocol for the duration of the study
Description

study compliance

Type de données

boolean

Alias
UMLS CUI [1]
C1321605
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
has significant leukopenia/lymphopenia (white blood cell count less than (<) 0.5 times the lower limit of normal)
Description

leukopenia/lymphopenia

Type de données

boolean

Alias
UMLS CUI [1,1]
C0023530
UMLS CUI [1,2]
C0023508
UMLS CUI [2]
C0024312
has elevated liver function tests (aspartate aminotransferase [ast], alanine transaminase [alt], or alkaline phosphatase greater than (>) 2 times the upper limit of normal or total bilirubin > 1.5 times the upper limit of normal)
Description

has elevated liver function tests

Type de données

boolean

Alias
UMLS CUI [1]
C0201899
UMLS CUI [2]
C0201836
UMLS CUI [3]
C1561546
UMLS CUI [4]
C0201913
has an allergy to human serum albumin or mannitol
Description

has an allergy to human serum albumin or mannitol

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0071512
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0024730
had treatment with an investigational product or procedure within 3 months
Description

had treatment with an investigational product or procedure within 3 months

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0013230
has the presence of systemic disease or abnormal laboratory findings that might interfere with subject safety, compliance or evaluation of the condition under study
Description

systemic disease interfering with study protocol compliance

Type de données

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
has concomitant use of avonex®, betaseron®, copaxone®, or novantrone®
Description

concomitant medication

Type de données

boolean

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0594372
UMLS CUI [2,1]
C2347852
UMLS CUI [2,2]
C0284968
UMLS CUI [3,1]
C2347852
UMLS CUI [3,2]
C0282248

Similar models

Eligibility Multiple Sclerosis, Relapsing-remitting NCT00292253

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
age
Item
greater than or equal to 18 years of age
boolean
C0001779 (UMLS CUI [1])
relapsing-remitting ms
Item
has relapsing-remitting ms
boolean
C0751967 (UMLS CUI [1])
study compliance
Item
are willing and able to comply with the protocol for the duration of the study
boolean
C1321605 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
leukopenia/lymphopenia
Item
has significant leukopenia/lymphopenia (white blood cell count less than (<) 0.5 times the lower limit of normal)
boolean
C0023530 (UMLS CUI [1,1])
C0023508 (UMLS CUI [1,2])
C0024312 (UMLS CUI [2])
has elevated liver function tests
Item
has elevated liver function tests (aspartate aminotransferase [ast], alanine transaminase [alt], or alkaline phosphatase greater than (>) 2 times the upper limit of normal or total bilirubin > 1.5 times the upper limit of normal)
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C1561546 (UMLS CUI [3])
C0201913 (UMLS CUI [4])
has an allergy to human serum albumin or mannitol
Item
has an allergy to human serum albumin or mannitol
boolean
C0020517 (UMLS CUI [1,1])
C0071512 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0024730 (UMLS CUI [2,2])
had treatment with an investigational product or procedure within 3 months
Item
had treatment with an investigational product or procedure within 3 months
boolean
C1514463 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
systemic disease interfering with study protocol compliance
Item
has the presence of systemic disease or abnormal laboratory findings that might interfere with subject safety, compliance or evaluation of the condition under study
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
concomitant medication
Item
has concomitant use of avonex®, betaseron®, copaxone®, or novantrone®
boolean
C2347852 (UMLS CUI [1,1])
C0594372 (UMLS CUI [1,2])
C2347852 (UMLS CUI [2,1])
C0284968 (UMLS CUI [2,2])
C2347852 (UMLS CUI [3,1])
C0282248 (UMLS CUI [3,2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial